Rapport Therapeutics
Edit info- Founded: 2022
- Location: Boston, MA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: Focal epilepsy
- Drug types: NEU
- Lead product: RAP-219
- Funding: $150M B Aug 2023; $100M A Mar 2023
- Investors: Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation – JJDC, Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital
rapportrx.com linkedin.com job board
Drug notes:
Also Clin1 neuropathic pain, Clin1 bipolar disorder; RAP-199 Clin0 undisclosed; 2 undisclosed programs RD pain, hearing disorders
About:
Rapport Therapeutics is identifying precision therapeutics to treat several central nervous system disorders. Central nervous systems disorders (CNS) are often treated with therapies that target the whole nervous system, while typically CNS diseases arise in specific cell types or restricted brain regions. Using their RAP technology platform, Rapport is creating small molecule therapies to deliver more effective and safer treatments. RAPs are receptor-associated proteins that enable Rapport to develop CNS drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. Rapport’s lead program, RAP-219, is in clinical trials for patients with focal epilepsy.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com